Year-end Sale % OFF 
Abstract
Fc receptors are important for the clinical efficacy of therapeutic antibodies. Bispecific antibodies (BsAb) are immunoglobulin-conjugates with two different binding specifities, targeting tumor antigens and effector cell trigger molecules. BsAb, produced by chemical coupling of one antibody against a tumor cell surface antigen with another against a Fc receptor, mediate effective interactions between effector and target cells.
Highlights
HLA DR-directed bispecific single-chain Fv antibodies for lymphoma therapy Y Wachter*, J Brünke, S Schuster, K Barbin, M Peipp, T Valerius, M Gramatzki, G Fey and R Repp
HLA class II and Lym-2 are both known as effective targets for effector cell-mediated lysis of malignant human B-lymphoid cells
Recombinant scFv against HLA class II, Lym-2, CD89 and CD16 were obtained from the hybridomas F3.3, Lym-2, A77 and 3G8 respectively
Summary
HLA DR-directed bispecific single-chain Fv antibodies for lymphoma therapy Y Wachter*, J Brünke, S Schuster, K Barbin, M Peipp, T Valerius, M Gramatzki, G Fey and R Repp. Email: Y Wachter* - Yvonne.Wachter@med3.imed.uni-erlangen.de * Corresponding author from Association for Immunotherapy of Cancer: Cancer Immunotherapy – 2nd Annual Meeting Mainz, Germany, 6–7 May 2004 Association for Immunotherapy of Cancer: Cancer Immunotherapy – 2nd Annual Meeting Meeting abstracts
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
